Olaparib liver injury

This case report highlights the need for close monitoring of liver tests while on olaparib and that the diagnosis of IM-DILI and prompt initiation of corticosteroids should be considered if an acute liver injury develops.

We report a case involving a 70-year-old female who experienced significant CTCAE Grade 4 hepatocellular injury after initiating first line maintenance Olaparib for Stage 3C HGSOC. Her liver injury resolved upon discontinuation of Olaparib but promptly recurred upon rechallenge.

olaparib 400 mg twice daily until disease progression.10 The primary liver injury.7. Owing to their mechanism of action, there was a

Based on this, she was diagnosed with olaparib-induced liver injury. She had a Roussel Uclaf Causality Assessment Method score of 12, suggesting high probability of drug-induced liver injury. Hence, olaparib was permanently discontinued on Novem, but her liver enzymes continued to increase to a peak of ALT 871U/L, AST 773U/ L, ALP

We report the first case in the United States of an acute and severe liver injury with associated jaundice and liver synthetic dysfunction secondary to olaparib. The liver injury was resolved with

liver disease (NAFLD). NAFLD is a chronic and progressive condition The company and AstraZeneca's Lynparza (olaparib) was also

In contrast, in aged female mice, olaparib treatment significantly reduced the CLP-induced liver injury markers ALP and ALT (Fig. 21). However, levels of the kidney injury marker BUN and pancreatic marker amylase were not affected by olaparib after injury.

This study shows that PARP is overactivated in livers of subjects with alcoholic liver disease and that pharmacological inhibition of this enzyme with 3 different PARP inhibitors, including olaparib, attenuates high fat or alcohol induced liver injury, abnormal metabolic alteration, fat accumulation, inflammation and/or fibrosis in preclinical

We report the first case in the United States of an acute and severe liver injury with associated jaundice and liver synthetic dysfunction secondary to olaparib. The liver injury was resolved with drug cessation and treatment with prednisone taper.